Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) Insider Sells 1,671 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) insider Gary Lee sold 1,671 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $39,084.69. Following the completion of the sale, the insider directly owned 16,938 shares of the company’s stock, valued at $396,179.82. The trade was a 8.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lyell Immunopharma Stock Up 4.3%

NASDAQ:LYEL traded up $1.04 on Thursday, hitting $25.38. The stock had a trading volume of 63,758 shares, compared to its average volume of 86,064. Lyell Immunopharma, Inc. has a 52 week low of $7.65 and a 52 week high of $45.00. The business’s fifty day moving average is $27.98 and its 200 day moving average is $19.64. The company has a market cap of $539.07 million, a PE ratio of -1.10 and a beta of -0.14.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Equities analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of hedge funds have recently bought and sold shares of the company. BBR Partners LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter worth $210,000. Marshall Wace LLP bought a new position in shares of Lyell Immunopharma during the second quarter valued at about $94,000. Jane Street Group LLC purchased a new position in Lyell Immunopharma during the fourth quarter worth about $382,000. Bridgeway Capital Management LLC bought a new stake in Lyell Immunopharma in the 2nd quarter worth about $159,000. Finally, Clarius Group LLC increased its stake in Lyell Immunopharma by 4.3% in the 3rd quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock valued at $324,000 after buying an additional 820 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on LYEL. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and upped their target price for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $45.00.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.